Table 6 Diagnostic performance of Stathmin, Transgelin, BCOR and Cyclin-D1 expressions in differentiation between Leiomyosarcoma (LMS) and Endometrial stromal sarcoma (ESS)

Stathmin

22

3

19

0

100%

86.4% (72-100)

88% (75.3-100)

100%

93.2% (85.()100)

Transgelin

19

0

22

3

86.4% (72-100)

100%

100%

88% (75.()100)

93.2% (85.7-100)

BCOR

19

4

18

3

86.4% (72-100)

81.8% (65.7-100)

82.6% (67.1-100)

85.7% (70.7-100)

84.1% (73.3-94.9)

Cyclin D1

22

2

20

0

100%

90.9% (78.()100)

91.7% (80.()100)

100%

95.5% (89.()100)

Stathmin & Transgelin

21

1

21

1

95.5% (86.()100)

95.5% (86.()100)

95.5% (86.()100)

95.5% (86.()100)

95.5% (89.()100)

Stathmin & BCOR

22

3

19

0

100%

86.4% (72-100)

88% (75.()100)

100%

93.2% (85.()100)

Stathmin & Cyclin D1

22

2

20

0

100%

90.9% (78.()100)

91.7% (80.()100)

100%

95.5% (89.()100)

Transgelin & BCOR

20

1

21

2

90.9% (78.()100)

95.5% (86.()100)

95.2% (86.()100)

91.3% (79.()100)

93.2% (85.()100)

Transgelin & Cyclin D1

22

1

21

0

100%

95.5% (86.()100)

95.7% (87.()100)

100%

97.7% (93.()100)

BCOR & Cyclin D1

20

1

21

2

90.9% (78.()100)

95.5% (86.()100)

95.2% (86.()100)

91.3% (79.()100)

93.2% (85.()100)

Stathmin, Transgelin & BCOR

21

1

21

1

95.5% (86.()100)

95.5% (86.()100)

95.5% (86.()100)

95.5% (86.()100)

95.5% (89.()100)

Stathmin, Transgelin & Cyclin D1

22

1

21

0

100%

95.5% (86.()100)

95.7% (87.()100)

100%

97.7% (93.()100)

Transgelin, BCOR & Cyclin D1

20

0

22

2

90.9% (78.()100)

100%

100%

91.7% (80.()100)

95.5% (89.()100)

Stathmin, BCOR & Cyclin D1

21

0

22

1

95.5% (86.()100)

100%

100%

95.7% (87.()100)

97.7% (93.()100)

Stathmin, Transgelin, BCOR & Cyclin D1

22

0

22

0

100%

100%

100%

100%

100%